Preclinical Evaluation of Novel PET Probes for Dementia

Romy Cools, Kobe Kerkhofs, Renan C.F. Leitao, Guy Bormans

    Research outputpeer-review


    The development of novel PET imaging agents that selectively bind specific dementia-related targets can contribute significantly to accurate, differential and early diagnosis of dementia causing diseases and support the development of therapeutic agents. Consequently, in recent years there has been a growing body of literature describing the development and evaluation of potential new promising PET tracers for dementia. This review article provides a comprehensive overview of novel dementia PET probes under development, classified by their target, and pinpoints their preclinical evaluation pathway, typically involving in silico, in vitro and ex/in vivo evaluation. Specific target-associated challenges and pitfalls, requiring extensive and well-designed preclinical experimental evaluation assays to enable successful clinical translation and avoid shortcomings observed for previously developed ‘well-established’ dementia PET tracers are highlighted in this review.

    Original languageEnglish
    Pages (from-to)599-629
    Number of pages31
    JournalSeminars in Nuclear Medicine
    Issue number5
    StatePublished - Sep 2023

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging

    Cite this